Advances in molecular diagnostics technology have sparked innovation, expanded research capabilities, and enhanced diagnostic capabilities. In precision oncology, companion and complimentary diagnostic testing in is critical in treatment decisions ranging from risk assessment and screening to therapy selection and monitoring progression.
From PCR, FISH, IHC technologies to now the expanding applications of next-generation sequencing (NGS), biomarker targeted therapies are improving clinical outcomes. Furthermore, applications of circulating tumor DNA (ctDNA) testing have provided options for less invasive procedures while also providing more accurate and precise evaluation of tumor heterogeneity.
NGS has tremendous power for interrogation of gene panels, transcriptome, whole-exome, and whole-genome genetic alterations. To improve access to NGS there are many challenges are opportunities to implement the needed bioinformatics and computing infrastructure and integrate laboratory results with clinical decision making tools.
VERI tracks 250+ oncology diagnostic tests across global jurisdictions and across all oncology indications. Pulling news and data from recent regulatory approvals, social media, trial data releases, conference abstracts and other research publications, VERI can keep you up to date on both the diagnostic market landscape and the latest applications of new diagnostic tests in oncology.
Explore the interactive map below by indication or biomarker to learn more about VERI Diagnostics Coverage. One can dig more by clicking on gene and cancer box to see type of evidence and latest news, tweets for the test.